Do you want to read an article? Please log in or register.
Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease
Related content
COMMENTED
PsoriasisRheumatoid Arthritis
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
doi: 10.1016/S2468-1253(19)30362-0.
Rheumatoid Arthritis
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration
Ann Rheum Dis.
Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C
doi: 10.1136/annrheumdis-
Rheumatoid Arthritis
Measuring inflammatory foot disease in rheumatoid arthritis: development and validation of the Rheumatoid Arthritis Foot Disease Activity Index-5
Arthritis Care Res (Hoboken).
Hoque A, Gallagher K, McEntegart A, Porter D, Steultjens M, Woodburn J, Hendry GJ
doi: 10.1002/acr.24259.
Rheumatoid Arthritis
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Ann Rheum Dis.
Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K, Tomšič M, Canhao H, Chatzidionysiou K, Lukina G, Nordström DC, Lie E, Ancuta I, Hernández MV, van Riel PL, van Vollenhoven R8, Kvien TK
doi: 10.1136/annrheumdis-2015-207760.
Rheumatoid Arthritis
Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
Ann Rheum Dis.
Aletaha D, Maa JF, Chen S, Park SH, Nicholls D, Florentinus S, Furtner D, Smolen JS
doi: 10.1136/annrheumdis-2018-214918.
Rheumatoid Arthritis
Latent class trajectory modelling of 2-components-DAS28 identifies multiple rheumatoid arthritis phenotypes of response to biologic disease modifying anti-rheumatic drugs
Arthritis Rheumatol.
Dagliati A, Plant D, Nair N, Jani M, Amico B, Peek N, Morgan AW, Isaacs J, Wilson AG, Hyrich KL, Geifman N, Barton A, BRAGGSS.
doi: 10.1002/art.41379.
PsoriasisPsoriatic ArthritisSpinal Disorders
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Ann Rheum Dis.
Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, Porter B, Das Gupta A, Pricop L, Fox T
doi: 10.1136/annrheumdis-2018-214273.
Rheumatoid Arthritis
Effects of Sarilumab on Patient-Reported Impact of Rheumatoid Arthritis Using the Rheumatoid Arthritis Impact of Disease Scale
J Rheumatol.
Gossec L, Strand V, Proudfoot C,
Chen CI, Guillonneau S, Kimura T, van Hoogstraten H, Mangan E, Reaney M
doi: 10.3899/jrheum.180904.
Rheumatoid Arthritis
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
JAMA
Lillegraven S, Paulshus Sundlisæter N, Aga AB, Sexton J, Olsen IC, Fremstad H, Spada C, Madland TM, Høili CA, Bakland G, Lexberg Å, Hansen IJW, Hansen IM, Haukeland H, Ljoså MA, Moholt E, Uhlig T, Solomon DH, van der Heijde D, Kvien TK, Haavardsholm EA
doi: 10.1001/jama.2021.4542